부산대학교 도서관

To link to full-text access for this article, visit this link: http://dx.doi.org/10.1016/j.jcrc.2006.05.002 Byline: Catherine S.C. Bouman (a), Heleen M. Oudemans-van Straaten (b), Marcus J. Schultz (a)(c), Margreeth B. Vroom (a) Keywords: Hemofiltration; Sepsis; SIRS; Mediator; Cytokine Abstract: The benefit of hemofiltration (HF) as an adjunctive treatment of sepsis or the systemic inflammatory response syndrome (SIRS) in critically ill patients is a subject of severe debate. Firm conclusions on this subject are hampered by the heterogeneity in study populations and HF treatments, and the lack of adequately sized randomized controlled clinical trials. The aim of this review was to determine the importance of ultrafiltration dose and timing on the physiologic and clinical effects of HF in sepsis and SIRS. In addition, we discuss the issue of filter pore size. Author Affiliation: (a) Department of Intensive Care, Academic Medical Center, University of Amsterdam, PO 22660, 1100 DD Amsterdam, The Netherlands (b) Laboratory of Experimental Intensive Care and Anesthesiology, Academic Medical Center, University of Amsterdam, 1100 DD Amsterdam, The Netherlands (c) Department of Intensive Care, Onze Lieve Vrouwe Gasthuis, PO 95500, 1090 HM Amsterdam, The Netherlands Article Note: (footnote) [star] CSCB performed the search, analyzed the data, and drafted the manuscript. HMO-vS contributed to the search. HMO-vS, MJS, and MBV critically reviewed the manuscript.